FDA Warning Letters · October 20, 2026 · Primary source
Rohto Pharmaceutical Co., Ltd.
Summary
FDA's CDER issued a warning letter dated October 14, 2026, to Rohto Pharmaceutical Co., Ltd., arising from an inspection of its Vietnam manufacturing facility, citing systemic data falsification across environmental monitoring, personnel monitoring, and cleaning records for aseptic ophthalmic drug production. The letter also identifies seven named over-the-counter Rohto cooling eye drop products as unapproved new drugs and misbranded under sections 505(a) and 502 of the FD&C Act. Rohto suspended U.S. distribution, but FDA found the firm's response inadequate because the product impact assessment relied on confirmed falsified data.
What this may mean
Seven Rohto OTC eye drop product lines are identified as unapproved and misbranded, making their continued distribution in the U.S. market unlawful under 21 U.S.C. 331. The systemic data integrity findings, including falsified environmental and cleaning records across multiple staff members and record types over an extended period, place the facility at significant risk of import alert, which would block future U.S. distribution until FDA confirms remediation. Pharmacies and retailers distributing these products face potential enforcement exposure for introducing adulterated or misbranded drugs into commerce.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Warning Letters · October 14, 2026SCA Pharmaceuticals, LLCScore 50
- FDA Warning Letters · October 20, 2026Signature Formulations LLCScore 46
- FDA Warning Letters · October 7, 2026Amazon.com, Inc.Score 46
- FDA Warning Letters · October 6, 2026Online Generic Medicine/www.onlinegenericmedicine.comScore 43
- FDA Warning Letters · October 20, 2026Olympus Medical Systems CorporationScore 40
- FDA Warning Letters · October 20, 2026Baxter International Inc.Score 38